Austin-based biotech company XBiotech is making headlines out of Texas today, having announced its recent findings for the effect that its True Human Therapeutic Antibody Xilonix has on Non-Small Cell Lung Cancer (NSCLC). Xilonix was used in in a study at the MD Anderson Cancer Center, treating sixteen advanced NSCLC patients, all of which had failed to achieve positive results from previous conventional therapy, and had progressive disease upon receiving Xilonix.
Impressively, over half of the patients treated with Xilonix recovered significant amounts of lean body tissue during treatment. Additionally, the patients in the study demonstrated a clear trend toward “improved overall physical and functional well-being,” according to an XBiotech press release.
Most impressive, however, is that overall survival outcomes in patients involved in the survey appeared to be significantly better than what is normally noted with late-stage NSCLC. The press release goes on to explain that:
Stratification of survival outcomes based on patient pretreatment history also provided some interesting findings. Sixty-three percent of the NSCLC patients treated in the study had actually received—and failed—previous treatment regimens with the anti-cancer agent TarcevaTM. Surprisingly, these patients appeared to have considerably better survival outcomes than patients with other pre-treatment histories.
The XBiotech does not provide quantified results in terms of how improved physical well-being and “significantly better” survival outcomes were measured, however, with deadly forms of cancer such as NSCLC, even modest improvements in quality of life and life expectancy are considered successes. Dr. Michael Stecher, XBiotech’s Medical Director, added: “We are very encouraged with the response to therapy seen in advanced NSCLC patients. Again we see that XILONIX treatment is associated with recovery from disease, and life extension.”
Be sure to research additional company information about XBiotech at BioNews Texas.